Anna Ludovica Fracanzani, Luca Valenti, Elisabetta Bugianesi, Marco Andreoletti, Agostino Colli, Ester Vanni, Cristina Bertelli, Erika Fatta, Daniela Bignamini, Giulio Marchesini, Silvia Fargion – 30 May 2008 – It is uncertain whether patients with nonalcoholic fatty liver disease (NAFLD) and normal alanine aminotransferase (ALT) have a milder disease and should undergo liver biopsy.

Shin Hwang, Sung‐Gyu Lee, Chul‐Soo Ahn, Ki‐Hun Kim, Deok‐Bog Moon, Tae‐Yong Ha, Gi‐Won Song, Dong‐Hwan Jung, Jung‐Ik Park, Je‐Ho Ryu, Hyo‐Jun Lee, Dong‐Jin Suh, Young‐Suk Lim – 28 May 2008 – The prevention of hepatitis B virus (HBV) recurrence is essential after liver transplantation in patients infected with HBV. We evaluated the efficacy of primary high‐dose hepatitis B immunoglobulin (HBIG) monotherapy and rescue antiviral therapy in 639 HBV‐infected adult patients who underwent living donor liver transplantation (LDLT) between February 1997 and December 2004.

Moshe Israeli, Tirza Klein, Benjamin Sredni, Yaron Avitzur, Eitan Mor, Nathan Bar‐Nathen, Ran Steinberg, Gabriel Dinari, Rivka Shapiro – 28 May 2008 – Lifelong immunosuppression is mandatory for optimal graft and patient survival following liver transplantation. Nevertheless, graft rejection or numerous adverse events associated with overimmunosuppression or underimmunosuppression cannot be completely avoided. The ImmuKnow assay measures cell‐mediated immunity and is able to discern between conditions of overimmunosuppression and underimmunosuppression.

Daniel Benten, Martina Sterneck, Jens Panse, Xavier Rogiers, Ansgar W. Lohse – 28 May 2008 – The incidence of de novo malignancies is increased in organ transplant recipients, and patients with hepatic carcinomas are at high risk for tumor recurrence after liver transplantation. Data about recurrent cancer after orthotopic liver transplantation (OLT) in patients with a history of nonhepatic malignancy are very limited. We retrospectively analyzed data from 606 adult OLT recipients and identified 37 patients (6.1%) with a preexisting extrahepatic malignancy.

28 May 2008

Vicente Arroyo, Javier Fernandez, Antoni Mas, Angels Escorsell – 28 May 2008

Nicholas A. Shackel, Geoffrey W. McCaughan, Fiona J. Warner – 28 May 2008

Simone Carotti, Sergio Morini, Stefano Ginanni Corradini, Maria Antonella Burza, Antonio Molinaro, Guido Carpino, Manuela Merli, Adriano De Santis, Andrea Onetti Muda, Massimo Rossi, Adolfo Francesco Attili, Eugenio Gaudio – 28 May 2008 – Activated alpha‐smooth muscle actin (α‐SMA)–positive hepatic stellate cells (HSCs) are pericytes responsible for fibrosis in chronic liver injury. The glial fibrillary acidic protein (GFAP), commonly expressed by astrocytes in the central nervous system, is expressed in vivo in the liver in a subpopulation of quiescent stellate cells.

Chiara Braconi, Tushar Patel – 28 May 2008

Peter N. Morcos, Barbara Brennan, Patrick F. Smith – 28 May 2008